Vaginal microbicides save money: A model of cost-effectiveness in South Africa and the USA

Sexually Transmitted Infections

Volumn 86, Issue 3, 2010, Pages 212-216

  Verguet, Stéphane ^a,b   Walsh, J A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; SOUTH AFRICA; UNITED STATES; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; CONDOMS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SOUTH AFRICA; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77953734920     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2009.037176     Document Type: Article

References (30)

1. UNAIDS. AIDS epidemic update: December 2007. Geneva: UNAIDS, 2007.
2. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005;308:1581-3.
3. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides? Science 2008;321:532-4.
4. Abdool Karim S, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% Pro2000/5 for the prevention of HIV infection in women: results of the HPTN 035 Trial. XVIth Conference on Retroviruses and Opportunistic Infections. Palais des Congres de Montreal, Montreal, Canada, 8-11 February 2009 [abstract 48-LB].
5. Wilson DP, Coplan PM. Mathematical models and health economic aspects of microbicides. Curr Opin HIV AIDS 2008;3:587-92.
6. Grassly N, Garnett GP, Schwartlander B, et al. The effectiveness of HIV prevention and the epidemiological context. Bull WHO 2001;79:1121-32. (Pubitemid 34084005)
7. Watts C, Vickerman P. The impact of microbicides on HIV and STD transmission: model projections. AIDS 2001;5(Suppl 1):543-4.
8. Vickerman P, Watts C, Delany S, et al. The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 2006;33:397-495.
9. Marseille E, Kahn JG, Billinghurst K, et al. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. Soc Sci Med 2001;52:135-48.
10. Foss AM, Vickerman PT, Heise L, et al. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003;17:1227-37.
11. Pinkerton SD, Abramson PR. The Bernoulli-process model of HIV transmission: applications and implications. In: Holtgrave DR, ed. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press, 1998. Chapter 2.
12. Fox-Rushby J, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001;16:326-31. (Pubitemid 32911160)
13. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy. Evidence of continuing racial and ethnic differences. AIDS 2006;43:451-7.
14. Bradshaw D, Groenewald P, Lauscher R, et al. Initial burden of disease estimates for South Africa, 2000. Cape Town: South African Medical Research Council, 2003.
15. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res 1999;8:471-80.
16. Cleary S, Bouille A, McIntyre D, et al. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township; 2004. Cape Town: Health Trust Systems, Médecins Sans Frontières, University of Cape Town Publication, 2004.
17. Pharmaco-Economics Working Group, The Rockefeller Foundation Microbicide Initiative. The economics of microbicide development: a case for investment. New York City: Rockefeller Foundation, 2002.
18. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006;3:48-56. (Pubitemid 43204370)
19. District of Columbia, Department of Health. HIV/AIDS administration. District of Columbia HIV/AIDS epidemiology annual report, 2007. Washington DC: District of Columbia Department of Health, 2007.
20. Myer L, Mathews C, Little F. Condom use and sexual behaviors among individuals procuring free male condoms in South Africa. A prospective study. Sex Transm Dis 2002;29:239-41.
21. Lauman EO. The social organization of sexuality: sexual practices in the United States. Chicago (IL): The University of Chicago Press, 1994.
22. UNAIDS. Epidemiological fact sheet on HIV/AIDS and sexually transmitted infections, December 2006. Geneva: UNAIDS, 2006.
23. Centers for Disease Control and Prevention, Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, McQuillan G, Kruszon-Horan D. HIV infection in the United States household population aged 18-49 years: results from 1999-2006. January 2008, No.4. Atlanta (GA): Centers for Disease Control and Prevention, 2008.
24. Padian NS, Shiboski SC, Glass SO, et al. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: results from a ten-year study. Am J Epidemiol 1997;146:350-7.
25. Man CY, Deeter RG, Benton M, et al. Low condom use among sexually active adults in the United States. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003. Chicago, 13-17 September 2003 [abstract L-1076]. Sponsored by the American Society for Microbiology.
26. Artz L, Macaluso M, Brill I, et al. Effectiveness of an intervention promoting the female condom to patients at sexually transmitted disease clinics. Am J Public Health 2000;90:237-44. (Pubitemid 30062676)
27. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997;44:1303-12.
28. Bertozzi S, Padian NS, Wegbreit J, et al. HIV/AIDS prevention and treatment. In: Jamison DT, ed. Disease control priorities in developing countries. Washington, DC, 2006. Chapter 18.
29. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male crcumcision for HIV prevention in a South African setting. PLoS Med 2006;3:2349-58. (Pubitemid 46026452)
30. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted disease among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-19.